HODGKIN S AND NON-HODGKIN S LYMPHOMA

Transcription

1

2

3 HODGKIN S AND NON-HODGKIN S LYMPHOMA edited by JOHN P. LEONARD, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University New York Presbyterian Hospital New York, NY MORTON COLEMAN, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University New York Presbyterian Hospital New York, NY 1 3

4 John P. Leonard, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University The New York Presbyterian Hospital New York, New York Morton Coleman, MD Center for Lymphoma and Myeloma Weill Medical College of Cornell University The New York Presbyterian Hospital New York, New York HODGKIN S AND NON-HODGKIN S LYMPHOMA Library of Congress Control Number: ISBN-10: e-isbn-10: ISBN-13: e-isbn-13: Printed on acid-free paper Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed in the United States of America springer.com

5

6 vi Hodgkin's and Non-Hodgkin's Lymphoma 8. Blood and Marrow Transplantation for Patients 251 with Hodgkin's and Non-Hodgkin's Lymphoma Ian W. Flinn, MD, PhD and Jesus G. Berdeja 9. Vaccine Therapies for Non-Hodgkin's Lymphomas 283 Sarah Montross, MD and John M. Timmerman, MD 10. Management of Early Stage Hodgkin's Lymphoma 317 David J. Straus, MD 11. Management of Advanced Stage Hodgkin's 333 Lymphoma Nancy L. Bartlett, MD and Avram J. Smukler, MD 12. Nodular Lymphocyte Predominant Hodgkin's 353 Disease Carol S. Portlock, MD 13. Lymphoma Imaging: Nuclear Medicine 363 Lale Kostakoglu, MD and Stanley J. Goldsmith, MD 14. Novel Small Molecules in the Treatment 413 of Lymphomas John Gerecitano, MD, PhD and Owen A. O'Connor, MD, PhD INDEX 461

7 FOREWORD The lymphomas are the most common malignancies where the tools of the medical oncologist serve as the principal treatment modality and can frequently result in cure of the patient. Over the past several decades, the use of chemotherapy for lymphoma has rapidly evolved to allow for improvements in efficacy as well as the reduction in some short and long term toxicities. Targeted therapies, such as unlabeled and radiolabeled monoclonal antibodies, have enhanced outcomes for patients with Band T cell malignancies. In parallel, advances in molecular biology, pathology and imaging have provided a better understanding of the pathogenesis of lymphoma to define new therapeutic strategies and have allowed for more accurate determination of prognosis to better define therapy. In this volume, we have asked a distinguished group of lymphoma researchers to summarize the state of the art in some of the most important aspects of the disease. The result is a current review of our knowledge of the lymphomas, standard diagnostic and therapeutic approaches, as well as our views on the most promising new directions. We hope that this information provides value to anyone working in the field, for both "lymphomanics" who focus in these diseases and for those for whom dealing with lymphoma is a minor but important part of their activities. We are grateful to many individual for their contributions to this work. Dan Muss spent many hours in formatting and editing texts, without which there would be no end result. Laura Walsh and Maureen Tobin from Springer very valiantly tried (unsuccessfully) to keep us on schedule. We are grateful to them for their patience and for the opportunity to participate in this project. A book of this nature is only as good as its contributors. We are extremely appreciative of our friends and colleagues made so many efforts in putting together this review. Our authors have provided an outstanding summary of current information, which clearly reflects an enormous effort particularly given all of their other ongoing projects and priorities. As with any of our academic efforts, this project would have been impossible without the support of our families. They constantly accept the many diversions of time and attention toward scientific and clinical activities with understanding and grace. Most importantly, we appreciate the contributions of our patients. We learn so much from them on a daily basis, as well as through their participation in research, without which there would be no progress. It is our most sincere hope that in the near future we can reach a point where all lymphoma patients can be cured. John P. Leonard, M.D. Morton Coleman, M.D.

8 CONTRIBUTING AUTHORS Nancy L. Bartlett, MD, Associate Professor of Medicine, Washington University, Siteman Cancer Center, Division of Medical Oncology, StLouis, MO Jesus G. Berdeja, MD, Assistant Professor of Medicine, School of Medicine, Lorna Linda University, Lorna Linda, CA Ethel Cesarman, MD, PhD, Associate Professor of Pathology, Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University and The New York Presbyterian Hospital, NewYork, NY Amy Chadburn, MD, Professor of Pathology and Laboratory Medicine, Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY Director, Immunopathology Laboratory, New York Presbyterian Hospital, NY April Chiu, MD, Assistant Professor of Pathology, Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY Morton Coleman, MD, FACP, Clinical Professor of Medicine, Weill Medical College of Cornell University, New York, NY Andrew M. Evens, DO, MS, Instructor in Medicine and Associate Director, Hematology/Oncology Training Program, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL Richard I. Fisher, MD, Samuel E. Durand Professor of Medicine, Director, Hematology-Oncology Unit, Director of Cancer Services, Strong Health, Director, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY Ian W. Flinn, MD, PhD, Associate Professor of Oncology, Director, Lymphoma Program; Assistant Director for Clinical Research, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

9 x Hodgkin's and Non-Hodgkin's Lymphoma Jonathan W. Friedberg, MD, Associate Director, Lymphoma Clinical Research, James P. Wilmot Cancer Center; Assistant Professor of Medicine and Oncology, University of Rochester Medical Center, Rochester, NY Richard R. Furman, MD, Assistant Professor, Weill Medical College of Cornell University, Department of Medicine, Division of Hematology and Oncology, New York, NY John Gerecitano, MD, PhD, Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY Stanley J. Goldsmith, MD, Director, Division of Nuclear Medicine, The New York Presbyterian Hospital; Professor of Radiology and Medicine, Weill Medical College of Cornell University, New York, NY Lale Kostakoglu, MD, Associate Professor of Radiology at the Weill Medical College of Cornell University, Department of Radiology, Division of Nuclear Medicine, The New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY John P. Leonard, MD, Director of the Oncology Unit, New York Presbyterian Hospital, Assistant Professor of Medicine at the Weill Medical College of Cornell University, Medical Director of the Center for Lymphoma and Myeloma at NYPH-Cornell, New York, NY Peter McLaughlin, MD, Professor of Medicine, University of Texas M.D. Anderson Cancer Center, Department of LymphomalMyeloma, Houston, TX Enrique A. Mesri, PhD, Laboratory of Viral Oncogenesis, Division of Hematology-Oncology, Department of Medicine, Weill Medical College of Cornell University and The New York Presbyterian Hospital, NY, NY Sarah Montross, MD, Department of Medicine, University of California, Los Angeles Center for Health Sciences, Los Angeles, CA Daniel Muss, Regulatory Coordinator, Weill Medical College of Cornell University, Department of Medicine, Division of Hematology and Oncology, New York, NY

10 Hodgkin's and Non-Hodgkin's Lymphoma xi Owen A. O'Connor, MD, PhD, Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, New York, NY Carol S. Portlock, MD, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York Christiane Querfeld, MD, Department of Dermatology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Steven T. Rosen, MD, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Avram J. Smukler, MD, Fellow, Hematology/Oncology, Washington University, Siteman Cancer Center, Division of Medical Oncology, St. Louis, MO David J. Straus, MD, Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Professor of Clinical Medicine, Weill Medical College of Cornell University, New York, NY John M. Timmerman, MD, Assistant Professor of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, CA